{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-070501","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2026-06-04T20:04:26+00:00","discovered_at":"2026-06-04T20:05:00.217748+00:00","generated_at":"2026-06-04T20:05:09.032859+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quoin Pharma gets Japan MHLW Orphan Drug Designation for QRX003 in Netherton Syndrome","bullets":["Japan MHLW granted Orphan Drug Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.","Designation provides incentives including up to 10 years of market exclusivity upon approval, priority review, and tax breaks.","Adds to prior U.S. FDA Orphan Drug, Pediatric Rare Disease, and Fast Track designations, plus EMA Orphan Drug Designation.","Quoin plans to self-commercialize QRX003 in Japan, U.S., and Western Europe; pivotal Phase 3 study expected H2 2026, NDA filing in 2027.","Company working with Japanese clinicians to refine clinical/regulatory pathway for approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-070501","json":"https://secwatch.observer/filing/0001104659-26-070501.json","markdown":"https://secwatch.observer/filing/0001104659-26-070501.md","text":"https://secwatch.observer/filing/0001104659-26-070501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926070501/0001104659-26-070501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926070501/tm2616916d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:05:09.032859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}